Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 2
2020 2
2021 6
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction.
van Eijck CWF, Strijk G, Vietsch EE, van der Sijde F, Verheij M, Mustafa DAM, Vink M, Aerts JGJV, van Eijck CHJ, Willemsen M. van Eijck CWF, et al. Among authors: van der sijde f. Eur J Cancer. 2024 Jan;196:113440. doi: 10.1016/j.ejca.2023.113440. Epub 2023 Nov 17. Eur J Cancer. 2024. PMID: 37988843 Free article.
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
van der Sijde F, Dik WA, Mustafa DAM, Vietsch EE, Besselink MG, Debets R, Koerkamp BG, Haberkorn BCM, Homs MYV, Janssen QP, Luelmo SAC, Mekenkamp LJM, Oostvogels AAM, Smits-Te Nijenhuis MAW, Wilmink JW, van Eijck CHJ; Dutch Pancreatic Cancer Group. van der Sijde F, et al. Front Immunol. 2022 Aug 25;13:898498. doi: 10.3389/fimmu.2022.898498. eCollection 2022. Front Immunol. 2022. PMID: 36091056 Free PMC article.
Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer.
Strijker M, van der Sijde F, Suker M, Boermeester MA, Bonsing BA, Bruno MJ, Busch OR, Doukas M, van Eijck CH, Gerritsen A, Groot Koerkamp B, Haj Mohammad N, van Hilst J, de Hingh IH, van Hooft JE, Luyer MD, Quintus Molenaar I, Verheij J, Waasdorp C, Wilmink JW, Besselink MG, van Laarhoven HW, Bijlsma MF; Dutch Pancreatic Cancer Group. Strijker M, et al. Among authors: van der sijde f. HPB (Oxford). 2021 Dec;23(12):1886-1896. doi: 10.1016/j.hpb.2021.05.001. Epub 2021 May 19. HPB (Oxford). 2021. PMID: 34103247 Free article.
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
van Eijck CWF, de Koning W, van der Sijde F, Moskie M, Groot Koerkamp B, Homs MYV, van der Burg SH, van Eijck CHJ, Mustafa DAM. van Eijck CWF, et al. Among authors: van der sijde f. Eur J Cancer. 2023 Mar;181:119-134. doi: 10.1016/j.ejca.2022.12.024. Epub 2022 Dec 28. Eur J Cancer. 2023. PMID: 36652890 Free article.
Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.
van der Sijde F, Azmani Z, Besselink MG, Bonsing BA, de Groot JWB, Groot Koerkamp B, Haberkorn BCM, Homs MYV, van IJcken WFJ, Janssen QP, Lolkema MP, Luelmo SAC, Mekenkamp LJM, Mustafa DAM, van Schaik RHN, Wilmink JW, Vietsch EE, van Eijck CHJ. van der Sijde F, et al. Ther Adv Med Oncol. 2021 Aug 18;13:17588359211033704. doi: 10.1177/17588359211033704. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34422118 Free PMC article.
16 results